Daniel Green, MSc


Former CEO of Phagenesis (Affiliated with Nestlé Health Science1), and VC at HBM Partners, Dresdner Kleinwort Benson and MVM.

Served as a Director of more than a dozen biotech and medtech and other company boards in the US, UK and France since 1998, as well as having been a board observer on company boards in Benelux, Germany and Switzerland. Has a BSc in Physics and Philosophy from the University of Bristol, and an MSc in The Structure and Organisation of Science and Technology from the University of Manchester.

1. In September 2016 Nestlé Health Science (NHSc) and Phagenesis entered into a staged, milestone-based acquisition of Phagenesis, a medical device company that has developed a new treatment for dysphagia.